Related Experiment Video
Updated: Aug 1, 2025
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
247
Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway
Shu Li1, Guangli Li2, Xiaoyan Li3
1Department of Dermatology, Taizhou People's Hospital, Taizhou, P. R. China.
Summary
Etanercept effectively treats psoriasis by reducing inflammation and cell proliferation. It also promotes apoptosis and cell cycle arrest, offering a potential therapeutic strategy for this challenging skin condition.
Area of Science:
- Dermatology
- Immunology
- Cell Biology
Background:
- Psoriasis is a chronic inflammatory skin disease with recurrent episodes, posing significant treatment challenges.
- Etanercept, a tumor necrosis factor-alpha (TNF-α) inhibitor, is used for psoriasis but lacks efficacy in some patients.
- Identifying biomarkers and understanding etanercept's mechanisms are crucial for improving psoriasis treatment outcomes.
Purpose of the Study:
- To investigate the therapeutic mechanisms of etanercept in psoriasis treatment.
- To explore the role of high mobility group box 1 (HMGB1) in etanercept's efficacy.
Main Methods:
- Established lipopolysaccharide (LPS)-induced HaCaT cell and imiquimod (IMQ)-induced mouse models of psoriasis.
- Treated cell and mouse models with etanercept.
- Assessed the effects of etanercept on inflammation, cell proliferation, apoptosis, and cell cycle.
- Investigated the impact of HMGB1 knockdown and overexpression on etanercept's effects in vitro.
Main Results:
- Etanercept reduced inflammation and pathological changes in the IMQ-induced mouse model.
- In vitro, etanercept inhibited proliferation, reduced inflammation, and induced cell cycle arrest and apoptosis in LPS-treated HaCaT cells.
- HMGB1 knockdown enhanced etanercept's inhibitory effects, while HMGB1 overexpression reversed them.
Conclusions:
- Etanercept demonstrates therapeutic potential by inhibiting proliferation and inflammation while promoting cell cycle arrest and apoptosis in psoriatic models.
- Etanercept effectively ameliorates inflammation in a psoriasis-like mouse model.
- HMGB1 plays a significant role in modulating etanercept's therapeutic effects in psoriasis.
Related Concept Videos
01:24T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
185
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
185
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
210
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
210
01:15Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K